Physician profile

Andrew Kapsalis

Podiatrist · Avon, IN

NPI 1780093765

$37,458.35

in general payments reported to CMS, 2019-2025

34 companies · $1,724 in 2025

The $1,724 reported for 2025 was more than what 88% of Podiatrist providers received nationally (typical 2025 total: $260).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$23,375.00
Travel and Lodging$2,916.82
Food and Beverage$2,803.04
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program$545.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Fusion Orthopedics USA, LLC $20,206.32 2023-2025 Minilock
Summ Cott Medical $4,950.00 2019-2024
Biopoly LLC $3,270.00 2023-2024
Crossroads Orthopedics, LLC $2,695.29 2019-2020
Trilliant Surgical LLC. $1,998.45 2022-2024 Arsenal Sinus Support Plate, Arsenal Ankle 10 Hole 1/3 Tubular Plate
Paragon 28, INC. $1,305.61 2019-2022
Fusion Orthopedics, LLC. $799.98 2023
Stryker Corporation $748.33 2019-2025 Inbone, Augment Injectable, Infinity
Medshape, INC. $223.79 2023-2025 Dynanail Helix, Washer, 15 Mm, Dynanail
Flower Orthopedics Coporation $149.44 2022
Depuy Synthes Sales INC. $129.17 2020-2023 Quickanchor Orthocord, Motoband
Novastep INC. $126.45 2025 Nexis
Smith+Nephew, INC. $114.40 2020-2025 Grafix Pl, Stravix Pl, Collagenase Santyl
Kerecis Limited $113.73 2023-2025 Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide
Integra Lifesciences Corporation $65.17 2019-2025 Integra, Integra Dermal Regeneration Template, Primatrix
Show all 33 companies
CompanyGeneral paymentsYearsTop products
Abbvie INC. $60.75 2024
Orthofix Medical, INC. $58.27 2022-2025 Physio-Stim
Treace Medical Concepts, INC. $56.13 2022-2025
Boehringer Ingelheim Pharmaceuticals, INC. $47.39 2019
Paratek Pharmaceuticals, INC. $47.05 2024-2025 Nuzyra
Cardiovascular Systems INC. $38.65 2019
Vertex Pharmaceuticals Incorporated $32.35 2024-2025
Djo, LLC $29.28 2019-2022
Horizon Therapeutics Plc $29.03 2019
Alafair Biosciences, INC. $27.88 2022
Zimmer Biomet Holdings, INC. $27.34 2019-2020
Pacira Pharmaceuticals Incorporated $24.68 2019
Medtronic, INC. $18.56 2024 Intellis Adaptivestim
Access Pro Medical, LLC $15.35 2025 Matriderm
Organogenesis INC. $14.28 2024
Kci USA, INC. $13.39 2020
In2bones USA, LLC $10.99 2021
Arthrosurface Incorporated $10.85 2019

1 company reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$26,683.20 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Andrew Kapsalis

$37,458.35

in general payments reported 2019-2025

Years
2019-2025
Top company
Fusion Orthopedics USA, LLC
Context
The $1,724 reported for 2025 was more than what 88% of Podiatrist providers received nationally (typical 2025 total: $260).

https://glasscript.com/doctor/755865/andrew-kapsalis

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.